Phase II clinical trial of weekly administration of VP 16 213 in small cell bronchogenic carcinoma

M. H. Cohen, L. E. Broder, B. E. Fossieck, D. C. Ihde, J. D. Minna

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

VP-16-213 is clearly active in small cell bronchogenic carcinoma. Further, there appears to be no cross resistance between this drug and other commonly used agents in this disease. The response rate of 25% seen in this study, in a patient population with advanced disease, is comparable to the response rates for other active single agents including cyclophosphamide, adriamycin, vincristine, methotrexate, procarbazine, and the nitrosoureas. Furthermore, the very predictable and generally mild toxicity of this drug makes it a potentially ideal agent to use in combination regimens in small cell bronchogenic carcinoma.

Original languageEnglish (US)
Pages (from-to)489-490
Number of pages2
JournalCancer Treatment Reports
Volume61
Issue number3
StatePublished - Dec 1 1977

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this